05December

Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US ... Read more

03December

NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed o ... Read more

02December

Xultophy® demonstrates similar glucose control with reduced risk of hypoglycaemi ... Read more

29November

Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduce ... Read more

05December

Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US ... Read more

05December

Novo Nordisk A/S - Share repurchase programme ... Read more

29November

Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduce ... Read more

28November

Novo Nordisk A/S - Share repurchase programme ... Read more

13December

Guggenheim Securities Conference, Boston

01January

Silent period,

02February

Financial statement for the full year of 2016,

01April

Silent period,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
DEVOTE conference call 
 
Q3 financial results


Access the Q3 conference call and material



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.



Annual Report 2015


Download the Novo Nordisk Annual Report 2015